Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 85
"Ozempic Face" Prevention: A New Risk Model
A 2026 paper proposes an anatomy-driven risk model and four-phase prevention algorithm for GLP-1-associated facial aging.
BPC-157 Grey Market Risks and Quality
BPC-157 is sold online with no regulatory oversight. What COA testing can and cannot tell you about identity, purity, and contamination.
PT-141 Grey Market Risks and Quality
Grey-market PT-141 vials lack the controls of FDA-approved Vyleesi. What COA testing reveals about identity, purity, and contamination.
Retatrutide grey market risks
Retatrutide is unapproved and ineligible for compounding. Grey-market vials carry identity, purity, and contamination risks.
Semaglutide Grey Market Risks and Quality
Counterfeit Ozempic, compounded semaglutide salt forms, and dosing errors: what regulators have found and what a COA cannot tell you.
Semax Grey Market Risks and Quality Testing
Semax is sold online with no regulatory oversight outside Russia. What COA testing reveals about identity, purity, and contamination.
Tesamorelin Grey Market Risks and Quality
Tesamorelin is FDA-approved only for HIV lipodystrophy. Grey-market vials sold for off-label use carry identity, purity, and contamination risks.
Tirzepatide Grey Market Risks and Quality
Counterfeit Mounjaro pens, compounded tirzepatide after the shortage ended, and FDA recalls: what regulators have found and what a COA cannot tell you.
Semaglutide at 6 months: STEP trial data
Community posts report 80-90 lbs lost in six months on semaglutide. Here is what STEP trial data shows about timelines and plateaus.
Semaglutide in teens: who responds best?
A real-world study asks which adolescents respond best to semaglutide for obesity, moving beyond the STEP TEENS trial into clinical practice.
Semaglutide and beta-cell function in T1D
A 2026 case study reports preserved beta-cell function and stable blood sugar in a newly diagnosed type 1 diabetes patient treated with semaglutide.
Semaglutide cut fentanyl seeking in rats
A 2026 rat study found that single doses of semaglutide prevented cue-, drug- and stress-triggered fentanyl seeking. Human trials are next.